ArticleAnnals of surgical oncology2026
De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe clinical benefit of adjuvant epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in stage IB non-small-cell lung cancer (NSCLC) remains controversial. This study evaluated the impact of adjuvant EGFR-TKIs on long-term survival in a real-world cohort of patients with stage IB NSCLC.
methodsA total of 340 patients with resected stage IB EGFR-mutated NSCLC were included in this study and divided into two groups (TKI
resultsAmong 340 included patients, 46.8% (159/340) received an EGFR-TKI. Adjuvant EGFR-TKIs significantly improved 5-year disease-free survival (TKI
conclusionDespite the limitations of a retrospective design, our findings suggest that adjuvant EGFR-TKIs might be omitted in patients with stage IB NSCLC with tumors ≤ 3 cm, those with partial-solid tumors, or those without high-risk factors.
Indexed as
Identifiers
42563120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.